Research programme: ischaemia/reperfusion injury therapy - Medicure
Alternative Names: MC-5422Latest Information Update: 02 Nov 2009
At a glance
- Originator Medicure
- Class
- Mechanism of Action Purinergic P2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended Myocardial ischaemia; Reperfusion injury
Most Recent Events
- 02 Nov 2009 Suspended - Preclinical for Myocardial ischaemia in Canada (unspecified route)
- 02 Nov 2009 Suspended - Preclinical for Reperfusion injury in Canada (unspecified route)
- 17 Apr 2008 Preclinical development is ongoing